These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Regulation of surfactant phosphatidylcholine secretion from alveolar type II cells during Pneumocystis carinii pneumonia in the rat. Rice WR; Singleton FM; Linke MJ; Walzer PD J Clin Invest; 1993 Dec; 92(6):2778-82. PubMed ID: 8254031 [TBL] [Abstract][Full Text] [Related]
3. Comparison of dosages, intervals, and drugs in the prevention of Pneumocystis carinii pneumonia. Hughes WT Antimicrob Agents Chemother; 1988 May; 32(5):623-5. PubMed ID: 3260765 [TBL] [Abstract][Full Text] [Related]
4. Phospholipase activities of bronchoalveolar lavage fluid in rat Pneumocystis carinii pneumonia. Kernbaum S; Masliah J; Alcindor LG; Bouton C; Christol D Br J Exp Pathol; 1983 Feb; 64(1):75-80. PubMed ID: 6601489 [TBL] [Abstract][Full Text] [Related]
5. Effects of smoke inhalation on surfactant phospholipids and phospholipase A2 activity in the mouse lung. Oulton M; Moores HK; Scott JE; Janigan DT; Hajela R Am J Pathol; 1991 Jan; 138(1):195-202. PubMed ID: 1987765 [TBL] [Abstract][Full Text] [Related]
6. Effect of folinic acid on the capacity of trimethoprim-sulfamethoxazole to prevent and treat Pneumocystis carinii pneumonia in rats. D'Antonio RG; Johnson DB; Winn RE; van Dellen AF; Evans ME Antimicrob Agents Chemother; 1986 Feb; 29(2):327-9. PubMed ID: 3487285 [TBL] [Abstract][Full Text] [Related]
7. Alteration of surfactant proteins A and D in bronchoalveolar lavage fluid of Pneumocystis carinii pneumonia. Qu J; He L; Rong Z; Pan J; Chen X; Morrison DC; Li X Chin Med J (Engl); 2001 Nov; 114(11):1143-6. PubMed ID: 11729507 [TBL] [Abstract][Full Text] [Related]
9. Reduction of pulmonary surfactant in patients with human immunodeficiency virus infection and Pneumocystis carinii pneumonia. Hoffman AG; Lawrence MG; Ognibene FP; Suffredini AF; Lipschik GY; Kovacs JA; Masur H; Shelhamer JH Chest; 1992 Dec; 102(6):1730-6. PubMed ID: 1446480 [TBL] [Abstract][Full Text] [Related]
10. Resistance to trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia. Implication of folinic acid. Nunn PP; Allistone JC Chest; 1984 Jul; 86(1):149-50. PubMed ID: 6610537 [TBL] [Abstract][Full Text] [Related]
11. Pentamidine aerosol in prophylaxis and treatment of murine Pneumocystis carinii pneumonia. Girard PM; Brun-Pascaud M; Farinotti R; Tamisier L; Kernbaum S Antimicrob Agents Chemother; 1987 Jul; 31(7):978-81. PubMed ID: 3499116 [TBL] [Abstract][Full Text] [Related]
12. Generation of lyso-phospholipids from surfactant in acute lung injury is mediated by type-II phospholipase A2 and inhibited by a direct surfactant protein A-phospholipase A2 protein interaction. Arbibe L; Koumanov K; Vial D; Rougeot C; Faure G; Havet N; Longacre S; Vargaftig BB; Béréziat G; Voelker DR; Wolf C; Touqui L J Clin Invest; 1998 Sep; 102(6):1152-60. PubMed ID: 9739049 [TBL] [Abstract][Full Text] [Related]
13. Pneumocystis carinii pneumonia alters expression and distribution of lung collectins SP-A and SP-D. Atochina EN; Beck JM; Scanlon ST; Preston AM; Beers MF J Lab Clin Med; 2001 Jun; 137(6):429-39. PubMed ID: 11385364 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of caspofungin, a 1,3-β-D-glucan synthase inhibitor, on Pneumocystis carinii pneumonia in rats. Sun P; Tong Z Med Mycol; 2014 Nov; 52(8):798-803. PubMed ID: 25288652 [TBL] [Abstract][Full Text] [Related]
16. Correlation of organism burden and alveolar macrophage counts during infection with Pneumocystis carinii and recovery. Lasbury ME; Durant PJ; Bartlett MS; Smith JW; Lee CH Clin Diagn Lab Immunol; 2003 Mar; 10(2):293-302. PubMed ID: 12626457 [TBL] [Abstract][Full Text] [Related]
17. Functional impairment of bronchoalveolar lavage phospholipids in early Pneumocystis carinii pneumonia in rats. Su TH; Natarajan V; Kachel DL; Moxley MA; Longmore WJ; Martin WJ J Lab Clin Med; 1996 Mar; 127(3):263-71. PubMed ID: 9273359 [TBL] [Abstract][Full Text] [Related]